Financial reports and presentations

Vaccibody to adopt IFRS (International Financial Reporting Standards) and to explore a potential listing of its shares on the Nasdaq Global Market in the United States


  • Vaccibody to change its accounting standard to IFRS (International Financial Reporting Standards)
  • Vaccibody to explore a potential listing of its shares on the Nasdaq Global Market in the United States


Oslo, Norway, March 5, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announced today that Vaccibody has decided to change its financial reporting from NGAAP (Norwegian Generally Accepted Accounting Principles) and instead adopt IFRS (International Financial Reporting Standards) as its new accounting standard.

Vaccibody has experienced a continued growing international interest in its stock, including a significant increase in its international investor base which has led to the Company’s decision to change its accounting standard to IFRS. The above change will be adopted with effect from the Company’s annual report as of the financial year 2020.

In addition, Vaccibody has initiated a process to explore a possible listing of Vaccibody on the Nasdaq Global Market in the United States. This process reflects the continued clinical and strategic advancement of Vaccibody’s portfolio of innovative vaccines and novel immunotherapies as well as the growing interest of international investors in Vaccibody. The timing of any potential listing will be considered as part of this review process and any potential listing would be subject to prevailing equity capital markets conditions at such possible relevant time.


About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. The company has collaborations with Roche and Nektar Therapeutics within oncology. Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications including its second-generation COVID-19 vaccine program, VB10.COV2. Vaccibody’s shares are traded on Euronext Growth Oslo, a trading platform operated by Euronext, the leading pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at


Contact for Vaccibody

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509

Vaccibody AS 
Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway


Forward-looking Statement for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Go back